Lucent Growth is a specialized capital advisory firm serving healthcare and AI/technology companies across equity financings, debt structuring, and M&A transactions. We advise management teams and boards at every stage — from initial raise to strategic exit — with the rigor and discretion of an institutional partner.
Whether you are raising your first institutional round, structuring non-dilutive debt ahead of a commercial milestone, or evaluating a strategic transaction, Lucent Growth provides the process, the investor coverage, and the execution capability to get it done.
We advise on the full spectrum of equity financings — from seed and Series A rounds through growth equity, crossover financings, and pre-IPO raises. Our work begins well before the investor conversation: we help management teams build the narrative, stress-test the financial model, and position the company relative to market comparables and investor expectations. We then execute a structured, competitive process designed to maximize optionality and preserve founder leverage.
Non-dilutive capital is frequently the most efficient path forward for commercial-stage companies that have achieved revenue traction but are not yet positioned for a larger equity raise. We advise on the full range of debt instruments — venture debt, revenue-based financing, royalty financing, asset-backed credit, and government-linked structures — and we work with management teams to identify the optimal structure for their balance sheet, covenants they can live with, and lenders who understand the sector.
We advise on buy-side and sell-side mandates, as well as strategic partnership and licensing transactions — an increasingly relevant transaction type for biotech and digital health companies pursuing pharma partnerships or out-licensing arrangements. Our sell-side process is designed to create competitive tension, maximize valuation, and ensure management teams enter negotiations from a position of strength. Our buy-side work focuses on disciplined target identification, structured diligence, and efficient execution.
Healthcare and AI/technology are our only two verticals — not two of twelve. Every investor relationship we maintain, every diligence framework we apply, and every transaction we have executed sits within these two sectors. That concentration is deliberate, and it is what separates us from generalist advisory firms.
The healthcare capital market rewards advisors who understand the regulatory environment, the clinical development pathway, and the reimbursement landscape — not just the financial mechanics. We have built our practice around companies navigating FDA clearance, CE marking, clinical-stage financing, and the transition from development-stage to commercial-stage operations. We know what institutional healthcare investors look for, how they underwrite risk, and what separates a company that gets funded from one that doesn't.
The AI and technology investment landscape is moving at a pace that rewards advisors who are genuinely embedded in the sector. We focus on companies with durable differentiation — proprietary data assets, defensible technical moats, or a go-to-market position that creates structural advantages. We are particularly active at the intersection of AI and healthcare, where the convergence of clinical datasets, regulatory tailwinds, and enterprise adoption is creating a compelling capital formation opportunity.
We operate at the standard our clients' investors expect — not the standard typical of boutique advisory. Every engagement is resourced, documented, and executed as though it will be scrutinized by the most sophisticated counterparty in the room. Because it will be.
We run every mandate with the same structural discipline as a bulge-bracket engagement. This means a clearly defined process timeline, investor-grade materials that can withstand technical due diligence, a structured outreach protocol, and rigorous documentation at every stage. Founders who have worked with larger banks will recognize the standard. Those who haven't will be better prepared for what institutional investors expect.
Our investor network is built around depth, not breadth. We maintain direct, active relationships with institutional healthcare and AI investors — venture capital firms, growth equity funds, family offices with sector mandates, strategic corporate development teams, and credit providers who lend specifically into these industries. We do not mass-blast investor lists. Every introduction is qualified, warm, and specific to the mandate.
Before we accept a mandate, we conduct the same level of diligence on a company that we expect investors to conduct during a process. We review financials, assess the competitive landscape, stress-test the valuation narrative, and identify the questions that will come up in investor conversations. If we find material issues, we raise them before the process begins — not after the first investor call. This is how we protect our clients' credibility and our own.
Lucent Growth works with approximately 15 clients per year. That ceiling is intentional. It means every client receives the full attention of the senior principal — not a junior associate — from kick-off through close. We decline more mandates than we accept. We do this because selectivity is the foundation of the standard we hold ourselves to, and because a firm that takes every deal serves none of them well.
A representative sample of mandates advised by Lucent Growth. Client details disclosed with permission or anonymized where confidentiality is required.
Neuromodulation MedTech — non-dilutive debt raise to support US commercial expansion ahead of Series B.
ClosedImplantable combination product targeting metabolic disease — Series A to fund first-in-human study.
Confidential — available on requestSurgical data licensing platform — growth equity raise to scale enterprise health system partnerships.
Confidential — available on requestA structured, four-stage process applied consistently across every mandate — regardless of transaction type or company size.
We begin every engagement with a structured diagnostic: reviewing financials, assessing market position, evaluating the competitive landscape, and determining what the capital markets will actually support. We are direct about what we find. If the company is not ready to raise, we say so.
We build the investor-grade package from the ground up — narrative positioning, investor presentation, financial model, data room architecture, and a company profile tailored to the investor audience. Materials are held to the standard of what a sophisticated institutional investor expects to receive, not what a founder finds comfortable sending.
We execute a structured outreach process targeting investors whose mandate, stage focus, and check size align specifically with the client. Every introduction is preceded by a positioning conversation. We manage the full investor pipeline — inbound interest, follow-up requests, data room access, and Q&A — so management can stay focused on running the business.
We manage the back half of the process with the same intensity as the front. Term sheet negotiation, investor co-ordination, legal process management, and final close — we are present at every step and advocate for our client's interests at every point of friction.
We work with a limited number of clients each year. If you are building something significant in healthcare or AI/technology, we would like to understand your situation.
Request a Confidential DiscussionAll initial discussions are strictly confidential and carry no obligation.